Objective To examine the expression level of interferon⁃induced transmembrane protein1( IFITM1) and assess its clinical significance in colorectal cancer. Methods Tissue microarrays were constructed from 144 paraffin⁃embedded tissue blocks containing colorectal cancer with corresponding normal epithelium, and the expression of IFITM1 was tested by immunohistochemistry. The correlations between IFITM1 expression, the clinicopathological factors and overall survival rate were evaluated. Results Immuno⁃histochemistry demonstrated that strong ( 7�7%) , moderate ( 36�9%) and weak ( 55�4%) expression rate of IFITM1 in colonic cancer tissue were higher than those of adjacent noncancerous tissue( 7�7%,36�9% and 55�4%) ,with significant difference( P=0�044) . The strong ( 1�3%) , moderate ( 39�2%) and weak ( 59�5%) expression rate of IFITM1 in rectal adenocarcinoma showed no statistic sig⁃nificance compared with (5�1%, 36�9% and 58�2%), with no difference (P=0�569).The expression of IFITM1 was significantly correlated with histological differentiation ( P=0�031) . However, the gender, age, tumor location, depth of invasion, lymph node me⁃tastasis, and TNM stage had no significant correlation with IFITM1 expression. OS of colorectal cancer patients with high, moderate, low expression of IFITM1 were 34�3, 45�7 and 46�7 months( P=0�700) . Moreover, Kaplan⁃Meier survival analysis demonstrated that patients with higher IFITM1 expression had worse overall survival outcomes than those with lower levels of IFITM1 expression in rectal cancer ( P=0�037) . Mean survival of rectal cancer patients with IFITM1 high expression, moderate expression and low expression was 15�0, 42�7 and 50�1 months respectively. IFITM1 expression was not a significant negative prognostic factor for survival by univariate or multivariate analyses. Conclusion The results suggest that the expression of IFITM1 is associated with poor prognosis in rectal ade⁃nocarcinoma. IFITM1 may be a biomarker to predict prognosis in patients with rectal adenocarinoma.%目的：探讨干扰素诱导的跨膜蛋白1（ IFITM1）在结直肠癌中的表达及临床意义。方法收集144例具有完整临床病理资料的结直肠腺癌组织标本，运用组织芯片技术和免疫组化法检测IFITM1在结直肠癌及其对应癌旁组织中的表达，分析IFITM1表达与临床病理特征、总生存时间（ OS）的关系，以及影响预后的因素。结果 IFITM1在结肠腺癌组织中的高、中、低表达率分别为7�7％、36�9％、55�4％，癌旁组织中分别为3�1％、27�7％、69�2％，差异有统计学意义（ P＝0�044）；IFITM1在直肠腺癌组织中高、中、低表达率分别为1�3％、39�2％、59�5％，在癌旁组织中分别为5�1％、36�9％、58�2％，差异无统计学意义（P＝0�569）。 IFITM1表达水平和结直肠癌组织分化有关（P＝0�031），与年龄、性别、淋巴结转移、远处转移及TNM分期等无关（ P＞0�05）。 IFITM1高、中、低表达结直肠癌患者的中位OS分别为34�3个月、45�7个月和46�7个月（ P＝0�700）；结肠癌患者的中位OS分别为38�2个月、48�0个月和43�5个月；直肠腺癌患者的中位OS分别为15�0个月、42�7个月和50�1个月（ P＝0�037）。单因素和多因素分析显示，IFITM1的表达水平不是影响结直肠癌预后的因素。结论结直肠癌组织中IFITM1表达与组织分化无关。
展开▼
